Meet with... GE Ventures
Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA
March 15, 2016 from 11:30 AM to 14:00 PM (PDT)
$10 - $35
Accelerate your Innovation with a capital partner that can help scale your ideas and grow your company! GE Ventures' unrivaled access to a global network of GE expertise and resources along with investment capital can help bring business to the next level. GE Venture's investment themes include:
- Digital Health - Use of combinations of devices, sensors, software, services and data to improve patient care
- IT/Service - Software and connectivity solutions that improve efficiency and decision making
- Minimally Invasive Procedures - Devices that enable new less invasive methods to deliver therapies and diagnostics
- Precision Medicine - Life science tools and diagnostics that enable personalized care
Representatives from GE Ventures will be in attendance to give an overview presentation about the company's key areas of interest and funding opportunities. Following the presentation, don't miss this opportunity to introduce yourself to Alex DeWinter, Director, Healthcare Ventures during the networking lunch. And finally, for those companies who applied online and were approved, one-on-one meetings with GE Ventures will provide a forum to discuss your company.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on February 17th, 2016.
GE Ventures Participating Representative:
Alex de Winter | Director, Healthcare Ventures, GE Ventures
Alex de Winter invests in life science instrumentation and clinical diagnostics startups, leading GE Ventures' investment in Veracyte (VCYT). Alex joined GE Ventures from Mohr Davidow Ventures, where he served as a board director with On-Q-ity and board observer for CardioDx, Corventis, Crescendo Bioscience, didimi, DVS Sciences, and Personalis. He started his career as a research scientist with 454 Life Sciences (acquired by Roche) and Pacific Biosciences (PACB). Alex has an MBA from UC Berkeley, a Ph.D. in chemistry from Stanford, and graduated magna cum laude from Amherst College with a BA in English and Chemistry. When not working, Alex enjoys cooking and supporting/lamenting the Dallas Cowboys.
Connect with Alex:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until March 14th, 2016 (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on February 17th, 2016. Your application will be reviewed and you will be notified of acceptance by March 1st, 2016. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Johnson & Johnson Innovation, JLABS
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.